English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
United Kingdom550 mgTirzepatide 40 mg · Retatrutide 5 mg · MGF 2 mg · DSIP 2 mg · PEG-MGF 2 mg · BPC-157 2 mg
View all

Growth-hormone axis research

CJC-1295 + Ipamorelin

Unvalidated two-peptide GH-axis research blend (CJC-1295 no DAC plus ipamorelin)

Component-specific, lot-released results required; one aggregate percentage is insufficient · target, verify batch COACAS 170851-70-4RUO
Research statusNo Direct Combination Trial / Research Use Only
Supplied formTwo-component peptide mixture; each sequence, modification and counterion requires independent identification
Lead time10–18 days
CJC-1295 + Ipamorelin — Lot-specific lyophilized solid; confirm whether the quoted material is co-lyophilized or separately blended
CJC-1295 + Ipamorelin — Lot-specific lyophilized solid; confirm whether the quoted material is co-lyophilized or separately blended · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • No sleep, recovery, lean-mass, body-composition, anti-aging or metabolic benefit has been established for this blend
  • Scientifically supportable uses include two-analyte identification and quantitation, blend homogeneity and stability studies, and controlled in vitro comparison of GHRH-receptor and GHSR1a signalling with each single component as a control.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
170851-70-4
Formula
Not applicable — mixture or multi-component material
Molecular weight
Component-specific; no single molecular weight
Appearance
Lot-specific lyophilized solid; confirm whether the quoted material is co-lyophilized or separately blended
Purity
Component-specific, lot-released results required; one aggregate percentage is insufficient · target, verify batch COA
Storage
Store and ship according to the lot-specific COA and validated data for the exact two-component formulation. Separate-component stability does not establish co-lyophilized or reconstituted blend stability. Require component recovery, ratio retention, adsorption, degradation and freeze-thaw data for the specified diluent, container, concentration, light and temperature conditions.
MOQ
On request
Lead time
10–18 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about CJC-1295 + Ipamorelin

This item is a vendor-defined mixture of a non-DAC CJC-1295-related GHRH analogue and ipamorelin, a growth-hormone secretagogue receptor agonist. Receptor convergence makes combination research plausible, but the exact blend lacks direct controlled clinical validation. The best human ipamorelin PK/PD study used a 15-minute intravenous infusion, while the well-known CJC-1295 human half-life study used the DAC-conjugated molecule. Neither study validates a no-DAC co-lyophilized vial, its ratio, subcutaneous use or claimed outcomes.

  • No clinical indication applies
  • Appropriate research contexts include orthogonal component identification, quantitative ratio and vial-uniformity testing, forced degradation, adsorption and compatibility studies, and controlled in vitro GHRHR/GHSR1a signalling experiments
  • Human GH deficiency, body composition, recovery, sleep and anti-aging are not validated indications for the blend.

Mechanism context

The question the literature is testing

The non-DAC CJC-1295-related component is intended to activate the GHRH receptor, while ipamorelin activates GHSR1a. Distinct signalling pathways can converge on pituitary GH release, but the magnitude, timing, receptor desensitization and downstream IGF-1 response of this exact mixture have not been established. Preclinical selectivity findings for ipamorelin and clinical results from other GHRH/GHRP combinations do not prove synergy for this pair.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research
Routes reported in sources
SubcutaneousIntravenous
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • There is no combination-specific clinical safety, immunogenicity, toxicology or long-term exposure dataset
  • The 2014 ipamorelin postoperative-ileus trial did not meet its primary efficacy endpoint, and its intravenous formulation cannot validate a commercial blend
  • FDA's 2024 PCAC reviews proposed that ipamorelin-related and CJC-1295-related bulk substances not be added to the 503A Bulks List; advisory recommendations are not product approvals
  • FDA's current safety page separately identifies immunogenicity, aggregation, peptide-impurity, API-characterization and serious-adverse-event concerns for the related components; these signals must not be attributed to or dismissed for the exact blend without data
  • Both CJC-1295 and ipamorelin are prohibited at all times under WADA's 2026 S2.2.4 category
  • This material is not for human or veterinary administration.

Interactions reported in the literature

  • No validated stacking or combination protocol exists
  • Claims of compatibility or synergy with MK-677, BPC-157, insulin, thyroid drugs, corticosteroids, HGH or other secretagogues are unsupported for this material and may confound GH-axis and analytical endpoints
  • Laboratory mixtures require compound-specific compatibility and interference testing.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

CJC-1295 + Ipamorelin factory batch COAs

CJC-1295 + Ipamorelin 10 mg Factory batch COA protected previewCJC-1295 + Ipamorelin10 mg · WHJLP-CJCIPA510-260526-D
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Appearance or a perceived physiological response cannot establish authenticity
  • Require independent high-resolution intact mass and sequence-confirming MS/MS or peptide mapping for both components; chromatographic separation and component-specific purity; net peptide content confirming the stated 5 mg plus 5 mg amount and 1:1 ratio; blend homogeneity and vial-to-vial uniformity; counterion, water, residual solvent, impurity and degradant profiles; and formulation-specific stability
  • Explicitly distinguish no-DAC from DAC-conjugated CJC-1295
  • A single aggregate HPLC purity value is insufficient.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
CJCIPA-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the lot-specific COA and validated data for the exact two-component formulation. Separate-component stability does not establish co-lyophilized or reconstituted blend stability. Require component recovery, ratio retention, adsorption, degradation and freeze-thaw data for the specified diluent, container, concentration, light and temperature conditions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Raun 1998 is preclinical ipamorelin pharmacology. Gobburu 1999 is human intravenous ipamorelin PK/PD. Teichman 2006 evaluates DAC-conjugated CJC-1295, not the no-DAC component. Beck 2014 evaluates intravenous ipamorelin for postoperative ileus and did not show a significant primary-endpoint benefit. Broader secretagogue reviews and studies using sermorelin, GHRP-2 or GHRP-6 are indirect evidence. FDA's 2024 PCAC materials, current compounding-safety page and the 2026 WADA list provide regulatory, safety and anti-doping context. No cited source validates this exact blend.
  1. 01

    Ipamorelin, the first selective growth hormone secretagogue

    European Journal of Endocrinology · 1998 · peer-reviewed original research (preclinical pharmacology)

    Open source
  2. 02

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

    Pharmaceutical Research · 1999 · peer-reviewed original research (human Phase 1 PK/PD study)

    Open source
  3. 03

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    The Journal of Clinical Endocrinology & Metabolism · 2006 · peer-reviewed original research (randomized, placebo-controlled clinical trials)

    Open source
  4. 04

    Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

    International Journal of Colorectal Disease · 2014 · peer-reviewed original research (Phase 2 randomized controlled trial)

    Open source
  5. 05

    The safety and efficacy of growth hormone secretagogues

    Sexual Medicine Reviews · 2018 · peer-reviewed narrative review

    Open source
  6. 06

    Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels

    American Journal of Men's Health · 2017 · peer-reviewed original research (retrospective clinical cohort study)

    Open source
  7. 07

    An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs

    ProPublica · 2026 · investigative journalism (major nonprofit newsroom)

    Open source
  8. 08

    FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting -- Ipamorelin Bulk Drug Substance Nomination

    U.S. Food and Drug Administration · 2024 · regulatory briefing document (federal agency)

    Open source

Product FAQ

Questions buyers ask about CJC-1295 + Ipamorelin

What evidence supports the CJC-1295 no-DAC plus ipamorelin blend?+

The two components act at different GH-axis receptors, so a combined laboratory effect is mechanistically plausible. However, no qualifying controlled clinical trial of this exact no-DAC CJC-1295 plus ipamorelin mixture was identified. Quantitative claims such as a 4-5-fold larger GH pulse are not established for this product. Evidence from ipamorelin alone, DAC-conjugated CJC-1295, or other GHRH/GHRP pairs must remain clearly separated.

Can CJC-1295 no DAC be substituted with sermorelin, tesamorelin or DAC-conjugated CJC-1295?+

No automatic substitution is valid. These are different molecular entities with different sequences or modifications, pharmacokinetics, regulatory contexts and analytical specifications. A new component changes the mixture identity, ratio, stability and assay interpretation. Any comparison requires separate reference standards and a new validated experimental design.

What presentation and release evidence should a buyer request?+

Confirm whether the quote covers a finished co-lyophilized vial, a post-manufacture blend or two separate components. Request starting-material COAs plus finished-product results for both identities, component-specific purity and content, the stated 5 mg + 5 mg basis, ratio and vial uniformity, counterions, degradants and formulation-specific stability. The SKU label alone does not prove co-lyophilization, a 1:1 released ratio or blend stability.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Growth-hormone axis research

CJC-1295 without DAC

Tetrasubstituted GRF(1-29) analogue · no DAC · research use only

Purity
Lot-specific · Batch COA
CAS
446036-97-1
Latest batch COA available on request
Growth-hormone axis research

Ipamorelin

Stereochemically defined GHSR agonist pentapeptide

Purity
Target ≥ 99.0% · Batch COA
CAS
170851-70-4
Latest batch COA available on request
Growth-hormone axis research

Sermorelin

Amidated human GHRH(1-29) research reference

Purity
Lot-specific · Batch COA
CAS
86168-78-7
Latest batch COA available on request
Growth-hormone axis research

GHRP-2

Pralmorelin (GHRP-2) hexapeptide research reference · approved Japanese diagnostic product context is not transferable

Purity
Lot-specific · Batch COA
CAS
158861-67-7
Latest batch COA available on request